Pyra Maria, Lingappa Jairam R, Heffron Renee, Erikson David W, Blue Steven W, Patel Rena C, Nanda Kavita, Rees Helen, Mugo Nelly R, Davis Nicole L, Kourtis Athena P, Baeten Jared M
Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA.
Contraception. 2018 Apr;97(4):357-362. doi: 10.1016/j.contraception.2018.01.011. Epub 2018 Feb 17.
Studies that rely on self-report to investigate the relationship between hormonal contraceptive use and HIV acquisition and transmission, as well as other health outcomes, could have compromised results due to misreporting. We determined the frequency of misreported hormonal contraceptive use among African women with and at risk for HIV.
We tested 1102 archived serum samples from 664 African women who had participated in prospective HIV prevention studies. Using a novel high-performance liquid chromatography-mass spectrometry assay, we quantified exogenous hormones for injectables (medroxyprogesterone acetate or norethisterone), oral contraceptives (OC) (levonorgestrel or ethinyl estradiol) and implants (levonorgestrel or etonogestrel) and compared them to self-reported use.
Among women reporting hormonal contraceptive use, 258/358 (72%) of samples were fully concordant with self-report, as were 642/744 (86%) of samples from women reporting no hormonal contraceptive use. However, 42/253 (17%) of samples from women reporting injectable use, 41/66 (62%) of samples from self-reported OC users and 3/39 (8%) of samples from self-reported implant users had no quantifiable hormones. Among self-reported nonusers, 102/744 (14%) had ≥1 hormone present. Concordance between self-reported method and exogenous hormones did not differ by HIV status.
Among African women with and at risk for HIV, testing of exogenous hormones revealed agreement with self-reported contraceptive use for most women. However, unexpected exogenous hormones were identified among self-reported hormonal contraceptive users and nonusers, and an important fraction of women reporting hormonal contraceptive use had no hormones detected; absence of oral contraceptive hormones could be due, at least in part, to samples taken during the hormone-free interval. Misreporting of hormonal contraceptive use could lead to biased results in observational studies of the relationship between contraceptive use and health outcomes.
Research studies investigating associations between hormonal contraceptive use and HIV should consider validating self-reported use by objective measures; because both overreporting and underreporting of use occur, potential misclassification based on self-report could lead to biased results in directions that cannot be easily predicted.
依靠自我报告来研究激素避孕的使用与艾滋病毒感染及传播之间的关系以及其他健康结局的研究,可能会因误报而导致结果不可靠。我们确定了感染艾滋病毒和有感染艾滋病毒风险的非洲女性中激素避孕使用情况误报的频率。
我们检测了664名参与前瞻性艾滋病毒预防研究的非洲女性的1102份存档血清样本。使用一种新型的高效液相色谱 - 质谱分析法,我们对注射用(醋酸甲羟孕酮或炔诺酮)、口服避孕药(OC)(左炔诺孕酮或炔雌醇)和植入剂(左炔诺孕酮或依托孕烯)中的外源激素进行了定量,并将其与自我报告的使用情况进行比较。
在报告使用激素避孕的女性中,258/358(72%)的样本与自我报告完全一致,在报告未使用激素避孕的女性中,642/744(86%)的样本也是如此。然而,在报告使用注射剂的女性的42/253(17%)的样本、自我报告使用口服避孕药者的41/66(62%)的样本以及自我报告使用植入剂者的3/39(8%)的样本中未检测到可量化的激素。在自我报告的未使用者中,102/744(14%)的样本中存在≥1种激素。自我报告的方法与外源激素之间的一致性在艾滋病毒感染状态方面没有差异。
在感染艾滋病毒和有感染艾滋病毒风险的非洲女性中,对外源激素的检测表明大多数女性的自我报告避孕使用情况与检测结果相符。然而,在自我报告使用激素避孕的使用者和未使用者中都发现了意外的外源激素,并且报告使用激素避孕的女性中有相当一部分未检测到激素;口服避孕药激素的缺失至少部分可能是由于在无激素间隔期采集的样本。激素避孕使用情况的误报可能会导致在关于避孕使用与健康结局关系的观察性研究中出现有偏差的结果。
调查激素避孕使用与艾滋病毒之间关联的研究应考虑通过客观测量来验证自我报告的使用情况;由于使用情况的高估和低估都存在,基于自我报告的潜在错误分类可能会导致在难以轻易预测的方向上出现有偏差的结果。